novo glp 1 drugs asks FDA to prevent compounders from making GLP-1 knockoffs Novo Nordisk's oral GLP-1 drug

Our findings highlight the beneficial effects of GLP-1 RAs in improving survival and reducing adverse cardiac and kidney events in individuals with type 2 diabetes and AKD

PMID: 25791371

Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in women: diagnosis and treatment: number 11-2024

It is a microbiome-based approach to supporting one of the body most studied metabolic hormones

The good news lately is that significant evidence exists that supports a range of interventions to improve diabetes outcomes [3]

If your state opts in, you could access GLP-1s for weight management at significantly lower cost